Recent work from our laboratory has identified FcRn overexpression in human cancer and higher tumour accumulation in mice of an FcRn high-binding recombinant albumin variant42 promoting adoption for targeted albumin-drug fusion designs. This evidence concerns the gene FCGRT and neoplasm.